Please login to the form below

Not currently logged in
Email:
Password:

crizotinib

This page shows the latest crizotinib news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA OKs for Alecensa and Zelboraf

Roche gets FDA OKs for Alecensa and Zelboraf

cancer. Alecensa (alectinib) has been approved for second-line use after Pfizer’s Xalkori (crizotinib) in patients with ALK-positive non-small cell lung cancer (NSCLC) in the US since the

Latest news

More from news
Approximately 11 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment of non-small cell lung cancer (NSCLC) in which ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics